KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML.

Boglarka Gyurkocza, Rajneesh Nath, Stuart Seropian, Hannah Choe, Mark R Litzow, Camille Abboud, Nebu Koshy, Patrick Stiff, Benjamin Tomlinson, Sunil Abhyankar, James Foran, Parameswaran Hari, George Chen, Zaid Al-Kadhimi, Partow Kebriaei, Mitchell Sabloff, Johnnie J Orozco, Katarzyna Jamieson, Margarida Silverman, Koen Van Besien, Michael Schuster, Arjun Datt Law, Karilyn Larkin, Neeta Pandit-Taskar, Scott D Rowley, Pashna Munshi, Rachel Cook, Moshe Y Levy, Hillard M Lazarus, Brenda M Sandmaier, John M Pagel, Vijay Reddy, James MacDougall, Kathleen McNamara, Jennifer Spross, Elaina Haeuber, Madhuri Vusirikala, Akash Nahar, Avinash Desai, Sergio Giralt

J Clin Oncol 43(2) 201-213

PMID39298738
PMCIDPMC11709001
DOI10.1200/JCO.23.02018
发表日期2024-09-19
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:图像复核确认至少一个 KM 面板含可见 No. at risk 表。
摘要

摘要

PURPOSE: Older patients with relapsed or refractory AML (RR AML) have dismal prognoses without allogeneic hematopoietic cell transplantation (alloHCT). SIERRA compared a targeted pretransplant regimen involving the anti-CD45 radioconjugate 131I-apamistamab with conventional care. METHODS: SIERRA (ClinicalTrials.gov identifier: NCT02665065) was a phase III open-label trial. Patients age ≥55 years with active RR AML were randomly assigned 1:1 to either an 131I-apamistamab-led regimen before alloHCT or conventional care followed by alloHCT if initial complete remission (CR)/CR with incomplete platelet recovery (CRp) occurred. Initial response was assessed 28-56 days after alloHCT in the 131I-apamistamab group and 28-42 days after salvage chemotherapy initiation; patients without CR/CRp or with AML progression could cross over to receive 131I-apamistamab followed by alloHCT. The primary end point was durable complete remission (dCR) lasting 180 days after initial CR/CRp. Secondary end points were overall survival (OS) and event-free survival (EFS), assessed hierarchically in the intention-to-treat (ITT) population. RESULTS: The ITT population included 153 patients (131I-apamistamab [n = 76]; conventional care [n = 77]). In total, 44/77 conventional care arm patients crossed over and 40/77 (52%) received 131I-apamistamab and alloHCT, with six patients (13.6%) experiencing a dCR. In the ITT population, the dCR rate was significantly higher with 131I-apamistamab (17.1% [95% CI, 9.4 to 27.5]) than conventional care (0% [95% CI, 0 to 4.7]; P < .0001). The OS hazard ratio (HR) was 0.99 (95% CI, 0.70 to 1.41; P = .96), and the EFS HR was 0.23 (95% CI, 0.15 to 0.34), with HR <1 favoring 131I-apamistamab. Grade ≥3 treatment-related adverse events occurred in 59.7% and 59.2% of the 131I-apamistamab and conventional care groups, respectively. CONCLUSION: The 131I-apamistamab-led regimen was associated with a higher dCR rate than conventional care in older patients with RR AML. 131I-apamistamab was well tolerated and could address an unmet need in this population.

KM 提取结果

1 个 Figure · 3 个 KM 面板

进入结果中心
KM Figure3 个面板

FIG 2.

FIG 2. OS and EFS. (A) OS in the ITT population. (B) OS in patients who achieved dCR. (C) EFS in the ITT population assessed by actual time. The initial decreases in the Kaplan-Meier curves are due to the patients who failed to achieve initial CR/CRp within the protocol-specified timeframe or those who had induction treatment failure on the day of random assignment. (D) Prespecified exploratory subgroup analyses of EFS assessed by grouped survival analysis in the ITT population. Data are from the January 22, 2024 cutoff. CR, complete remission; CRp, CR with incomplete platelet recovery; dCR, durable complete remission; EFS, event-free survival; HR, hazard ratio; ITT, intention-to-treat; NE, not evaluable; OS, overall survival.

A

Overall Survival

FIG 2. · Panel A

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel A 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
B

Overall Survival

FIG 2. · Panel B

complete 待 EXE 对齐 预期 1 条 已提取 1 条

Panel B 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
C

Event-Free Survival

FIG 2. · Panel C

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel C 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIG 1.FIG 1. Trial profile. a Due to death (n = 1), investigator decision (n = 1), insurance (n = 1), did not meet eligibility criteria (n = 1). b Patient withdrew consent. c Due to investigator decision (n = 3), grade 3 infusion reaction (n = 1), rapid disease progression (n = 1), unfavorable biodistribution (n = 1). d Defined as <5% blasts in bone marrow within 28 to 42 days. e Due to decline in Karnofsky performance status (n = 2), investigator decision (n = 1), patient withdrew consent (n = 1). f Patients listed as relapsed had disease relapse but were alive at the time of last contact/data cutoff. g Investigator decision (n = 1), insurance (n = 1), did not meet eligibility criteria (n = 1). h At the primary cutoff (June 30, 2022). At the subsequent cutoff on January 22, 2024, eight patients were ongoing, with one having discontinued because of relapse. i At the primary cutoff (June 30, 2022). At the subsequent cutoff on January 22, 2024, four patients were ongoing, with two patients in the crossover group having died and one having completed 5-year survival follow-up. alloHCT, allogeneic hematopoietic cell transplantation; CR, complete remission; CRp, complete remission with incomplete platelet recovery; ITT, intention-to-treat; MLFS, morphologic leukemia-free state.
非 KM Figure